Prophylactic Anecortave Acetate in Patients With a Retisert Implant
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Retisert implant is an effective therapy for controlling inflammation in patients with
non-infectious posterior uveitis. One of the major complications of this device is the
development of elevated intraocular pressure (IOP) following implantation in 60% of patients.
Glaucoma filtering is required in over 30% of patients at 2 years. Anecortave acetate (AA)
has been shown to reduce steroid induced elevated IOP. The purpose of this study was to
evaluate the ability of prophylactic anterior juxtascleral depot administration of AA to
prevent this Retisert induced elevated IOP.